Amgen: Profile, Patents and Pipeline
Arrowhead Publishers, September 2005
Amgen is the world's largest biotechnology company and the eighth largest pharmaceutical company worldwide. Revenues have nearly doubled in the last three years, going from $5.52 billion in 2002 to $10.55 billion in 2004. Yet the majority of revenue is based on twenty-year old technology. Can Amgen continue its amazing revenue growth? Or will it fall behind, lacking the small molecule therapeutics that are the mainstay of modern pharmaceuticals?
This report provides an in-depth analysis of Amgen's
- Strategic strengths and weaknesses
- Current therapeutic products and pipeline of future products
- Financial analysis, including R& D productivity
- Current patents and patent applications
- Alliances, joint ventures and acquisitions
- Key personnel
Who should buy this report?
- Biotech and pharmaceutical companies of all sizes interested in understanding Amgen's rapid climb to success and its future direction
- Early stage biotechnology companies interested in understanding Amgen Ventures strategy for investing its $100 million
- Financial analysts looking for an in-depth technical analysis of Amgen's future revenue sources
Key reasons to purchase this report
- Competitive intelligence
- Benchmark company performance against the leading biotechnology company
- Understand what is driving Amgen's growth, and what is holding it back
This 81 page up-to-date report, based on information gathered through the end of the first quarter 2005, contains five tables on Amgen's pipeline; a listing of the last three years of granted patents, analyzed by therapeutic area as well as therapeutic form; a breakdown of sales for all key products; both U.S. and International, as well as a list of all patent applications for 2004 through the first quarter of 2005.
1 Overview
1.1 Lines of Business
1.2 Products
1.3 Technology
1.4 Marketing
1.5 Employees
2 Amgen Strategy
2.1 Amgen Strengths
2.2 Amgen Weaknesses
2.3 Amgen's Strategy Going Forward
2.3.1 The Quest for Small Molecule Therapeutics
2.3.2 R&D Productivity
2.3.3 Partnering with Smaller Biotechs
2.4 Amgen Ventures
2.4.1 Amgen Venture's First Investment - Accelerator
2.5 Potential Problems Facing Amgen
2.6 The Next Billion Dollar Therapeutic?
2.6.1 ENBREL® (etanercept)
2.6.2 Sensipar® (cinacalcet HCl)
2.6.3 Kepivance® (palifermin)
2.6.4 Panitumumab®
2.6.5 AMG 162
3 Key Events 2004
4 Key Products
4.1 EPOGEN®
4.2 Aranesp®
4.3 NEUPOGEN®
4.4 Neulasta®
4.5 ENBREL®
4.6 Additional Products
4.6.1 Kineret®
4.6.2 Sensipar®
4.6.3 Kepivance ™
5 Drug Pipeline
6 Recent Clinical Trials Results
7 Joint Ventures and Collaborations
7.1 Key Joint Ventures
7.1.1 Kirin Brewery Company, Limited
7.1.2 Wyeth
7.1.3 Johnson & Johnson
7.1.4 Genentech
7.1.5 NPS Pharmaceuticals
7.2 Additional Collaborations
7.2.1 GenData
7.2.2. Dyax
7.2.3 ZymoGenetics
7.2.4 Immunomedics
7.2.5 Cambridge Antibody Technologies
7.2.6 Infinity Pharmaceuticals
7.2.7 ViaCell, Inc.
7.2.8 Biovitrum
7.2.9 Epimmune
7.2.10 NeoGenesis Pharmaceuticals
7.2.11 Anadys Pharmaceuticals
7.2.12 Genome Therapeutics / Oscient Pharmaceuticals
7.2.13 BioFocus
7.2.14 Abgenix
7.2.15 Medarex
7.2.16 GenMab
8 Recent Acquisitions
9 Manufacturing and Suppliers
10 Litigation and Contract Disputes
10.1 Patent Disputes
10.1.1 Transkaryotic Therapies and Aventis
10.1.2 Israel Bio-Engineering
10.1.3 Columbia University
10.2 Class Action/Government Investigations
10.3 Contractual Disputes
10.4 Disputes Involving Amgen Medication
11 Amgen Financials
Discussion of Financials
12 Sales of Amgen Key Products
13 Amgen's US Patents
13.1 Amgen's US Granted Patents: 2002 - 2004
13.2 Amgen's 2004 Granted Patents
13.3 Amgen's 2003 Granted Patents
13.4 Amgen's 2002 Granted Patents
Appendix A Key Patent Expirations
Appendix B Amgen US Patent Applications: 2004 through 1st Quarter 2005
Appendix C Key Biographies
Tables
Table 5.1 Oncology Pipeline
Table 5.2 Inflammation Pipeline
Table 5.3 Metabolic Disorder Pipeline
Table 5.4 Neuroscience Pipeline
Table 5.5 General Medicine/Other Pipeline
Table 9.1 Amgen Products and Manufacturing Sites
Table 11.1 Three Year Key Financials
Graphs
Graph 12.1 Total Worldwide Product Sales, 2002-2004
Graph 12.2 2004 U.S. vs. International Sales of Products
Graph 12.3 Worldwide Sales of EPOGEN®, 2002-2004
Graph 12.4 Worldwide Sales of Aranesp®, 2002-2004
Graph 12.5 2004 U.S. vs. International Sales of Aranesp®
Graph 12.6 Worldwide Sales of NEUPOGEN® 2002-2004
Graph 12.7 2004 U.S. vs. International Sales of NEUPOGEN®
Graph 12.8 Worldwide Sales of Neulasta® 2002-2004
Graph 12.9 2004 U.S. vs. International Sales of NEULASTA®
Graph 12.10 Worldwide Sales of ENBREL® 2002-2004
Graph 12.11 2004 U.S. vs. International Sales of ENBREL®
Graph 13.1 Granted Patents Based on Therapeutic Area
Graph 13.2 Granted Patents Based on Therapeutic Form
Graph 13.3 Amgen 2004 Patents Based on Therapeutic Area
Graph 13.4 Amgen's 2004 Granted Patents Based on Therapeutic Form
Graph 13.5 Amgen 2003 Patents Based on Therapeutic Area
Graph 13.6 Amgen's 2003 Granted Patents Based on Therapeutic Form
Graph 13.7 Amgen's 2002 Granted Patents by Therapeutic Area
Graph 13.8 Amgen's 2002 Granted Patents by Therapeutic Form
Winifred Halsey has a Master's degree in Biology specializing in Microbiology and Molecular Biology. She is the principal of TechKnowledge Research, which provides market and competitive intelligence research and analysis to high technology companies. Prior to founding her own company in 1987, Ms. Halsey held various managerial and research positions at: Amersham Corporation, Baxter Laboratories, Abbott Laboratories, Northwestern University and Loyola University Medical Center.
John Heng obtained his PhD in Microbiology and Molecular Genetics from Harvard University in 1996. He joined Motorola's New Enterprises following graduation, working on biologically-related programs including biosensors, telemedicine, bioinformatics and precision agriculture.
He later moved to the Global Software Group of Motorola, working for its new business venture program, managing a team of internal business consultants who assisted with developing regional growth strategies for Latin America and the Asia-Pacific regions, new product platforms and business process development. John left Motorola in September of 2004 to pursue his own business ideas.
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
